RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC

[1]  P. Guzzi,et al.  Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter” , 2020, Journal of experimental & clinical cancer research : CR.

[2]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[3]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[4]  Na Liu,et al.  GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3–mediated deubiquitination of LSH , 2019, Oncogene.

[5]  Xiao Zhi Qiu,et al.  AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer , 2019, Molecular Cancer Therapeutics.

[6]  Chawnshang Chang,et al.  LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex , 2019, Nucleic acids research.

[7]  C. Tepper,et al.  Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer , 2018, Nature Communications.

[8]  J. Mendell,et al.  Functional Classification and Experimental Dissection of Long Noncoding RNAs , 2018, Cell.

[9]  Jinbao Liu,et al.  Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination , 2018, Oncogene.

[10]  Benjamin P. C. Chen,et al.  Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. , 2017, Cancer research.

[11]  A. Bhan,et al.  Long Noncoding RNA and Cancer: A New Paradigm. , 2017, Cancer research.

[12]  Y. Mo,et al.  LncRNA-mediated regulation of cell signaling in cancer , 2017, Oncogene.

[13]  R. DePinho,et al.  Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer , 2017, Nature.

[14]  Jinbao Liu,et al.  Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor , 2017, Cell Death & Disease.

[15]  D. Grignon,et al.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer , 2017, The New England journal of medicine.

[16]  Jun Lu,et al.  The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer , 2016, Cell Death and Differentiation.

[17]  M. Dinger,et al.  Long noncoding RNAs in cancer: mechanisms of action and technological advancements , 2016, Molecular Cancer.

[18]  Aaron J. Johnson,et al.  Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. , 2016, The Journal of clinical investigation.

[19]  R. Davey,et al.  Androgen Receptor Structure, Function and Biology: From Bench to Bedside. , 2016, The Clinical biochemist. Reviews.

[20]  Maite Huarte.  The emerging role of lncRNAs in cancer , 2015, Nature Medicine.

[21]  Jindan Yu,et al.  LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer , 2015, Cell reports.

[22]  M. Gleave,et al.  AR-v7 protein expression is regulated by protein kinase and phosphatase , 2015, Oncotarget.

[23]  P. Purushottamachar,et al.  Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo , 2015, Oncotarget.

[24]  H. Zhang,et al.  PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver Carcinogenesis. , 2015, Cancer research.

[25]  Shenghao Xu,et al.  Supplementary Information , 2014, States at War, Volume 3.

[26]  K. Rajapakshe,et al.  Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. , 2014, Cancer research.

[27]  Yezi Zhu,et al.  Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[28]  R. Matusik,et al.  Skp2 regulates androgen receptor through ubiquitin‐mediated degradation independent of Akt/mTOR pathways in prostate cancer , 2014, The Prostate.

[29]  J. Larner,et al.  Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells , 2014, Oncogene.

[30]  J. Rinn,et al.  Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination , 2013, Nature Communications.

[31]  D. Bowtell,et al.  The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. , 2013, Cancer cell.

[32]  P. Nelson,et al.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.

[33]  Howard Y. Chang,et al.  Genome regulation by long noncoding RNAs. , 2012, Annual review of biochemistry.

[34]  A. Weissman,et al.  HECT and RING finger families of E3 ubiquitin ligases at a glance , 2012, Journal of Cell Science.

[35]  Vasant Honavar,et al.  Predicting RNA-Protein Interactions Using Only Sequence Information , 2011, BMC Bioinformatics.

[36]  Howard Y. Chang,et al.  Molecular mechanisms of long noncoding RNAs. , 2011, Molecular cell.

[37]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[38]  J. Rinn,et al.  A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response , 2010, Cell.

[39]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[40]  G. Chrousos,et al.  Noncoding RNA Gas5 Is a Growth Arrest– and Starvation-Associated Repressor of the Glucocorticoid Receptor , 2010, Science Signaling.

[41]  Zhiyong Guo,et al.  A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. , 2009, Cancer research.

[42]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[43]  H. Scher,et al.  Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.

[44]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[45]  O. Ogawa,et al.  Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. , 2005, Cancer research.

[46]  C. Heinlein,et al.  Androgen receptor in prostate cancer. , 2004, Endocrine reviews.

[47]  S. Balk,et al.  Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence , 2004, Journal of cellular biochemistry.

[48]  Chawnshang Chang,et al.  Phosphorylation‐dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase , 2002, The EMBO journal.

[49]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[50]  I. Tannock,et al.  Drug resistance in metastatic castration-resistant prostate cancer , 2011, Nature Reviews Clinical Oncology.